on BIOMERIEUX (EPA:BIM)
BioMérieux's VITEK® COMPACT PRO Gains FDA Clearance
bioMérieux has secured FDA 510(k) clearance for its new VITEK® COMPACT PRO system. This system enhances microorganism identification and antibiotic susceptibility testing in clinical settings. The innovation aims to assist laboratories in controlling infectious diseases and combating antimicrobial resistance.
Antimicrobial resistance is a growing concern, complicating the detection of resistant pathogens. VITEK® COMPACT PRO offers rapid, accurate diagnostics ideally suited for small to medium laboratories. Its ergonomic design and simplified workflow aim to increase efficiency, reducing sample processing times for laboratory technicians.
The system's launch is slated for select markets in 2025, with a global rollout planned shortly after.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news